NASDAQ · DNLI
Denali Therapeutics Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for DNLI: Nov 03, 2026
Denali Therapeutics Inc. Common Stock is expected to report earnings on 11/03/2026 after market close. The report will be for the fiscal Quarter ending Sep 2026. According to Zacks Investment Research, based on 8 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.69. The reported EPS for the same quarter last year was $-0.74.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.69 | $-0.54 | $-0.88 | 8 |
| Dec 2026 | $-0.64 | $-0.48 | $-0.77 | 10 |
| Mar 2027 | $-0.58 | $-0.53 | $-0.64 | 2 |
| Jun 2027 | $-0.61 | $-0.58 | $-0.63 | 2 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
RTTNews · Zacks · BNK Invest · The Motley Fool- RTTNews · Oct 30, 2:11 PM EDTDenali Gains Biotech Recognition As AVLAYAH Validates Blood-Brain Barrier Platform(RTTNews) – Denali Therapeutics Inc. (DNLI) announced that AVLAYAH (tividenofusp alfa-eknm) has been named the 2026 Prix Galien USA Best Biotechnology Product by The Galien Foundation, recognizing its innovation in treating rare neurological diseases.
- Zacks · Oct 14, 9:30 AM EDTCan RARE's Approved Product Portfolio Drive Its Next Growth Phase?Ultragenyx's established rare-disease treatments continue to support revenue growth, while two newly approved gene therapies offer additional commercial opportunities.
- BNK Invest · Oct 6, 4:43 PM EDTDenali Therapeutics Enters Oversold Territory (DNLI)Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which me
- Zacks · Aug 20, 12:20 PM EDTDNLI Stock Gains 33.1% in Three Months: Buy, Sell or Hold the Stock?Denali's Avlayah launch drives strong uptake and a 33.1% three-month stock gain, but regulatory and pipeline risks remain.
- Zacks · Aug 20, 10:12 AM EDTShould You Buy, Sell or Hold Biogen Stock After a 9% Rise in a Month?BIIB's newer drugs, M&A activity and pipeline progress are fueling its turnaround, but declining MS sales remain a key risk.
- The Motley Fool · Aug 13, 6:32 PM EDTDenali Therapeutics (DNLI) Q2 2026 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
- Zacks · Aug 7, 2:31 PM EDTDNLI Q2 Loss Narrows, Avlayah Sales Drive Strong Launch MomentumDenali Therapeutics narrows Q2 loss as Avlayah sales top estimates, with strong launch traction and pipeline updates shaping its outlook.
- MarketBeat · Aug 6, 9:03 PM EDTDenali Therapeutics Q2 Earnings Call HighlightsAnalysts Say These 2 Mid-Cap Biotechs Have 2x PotentialDenali Therapeutics (NASDAQ:DNLI) reported $3.6 million in net product revenue from AVLAYAH during the second quarter of 2026, its first full quarter of commercial availability, as the company expanded payer access and advanc
- Zacks · Aug 6, 5:40 PM EDTDenali Therapeutics Inc. (DNLI) Reports Q2 Loss, Tops Revenue EstimatesDenali Therapeutics (DNLI) delivered earnings and revenue surprises of +5.56% and +143.35%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · Jul 15, 1:02 PM EDTWill Recent Setbacks Impact Growth Prospects of DNLI Stock?Denali Therapeutics gains FDA approval for Avlayah, but pipeline setbacks and partner exits raise fresh questions as key clinical programs continue.
- Zacks · Jul 8, 2:05 PM EDTDNLI Stock Surges 59.4% Year to Date: Is There More Room for Growth?Denali Therapeutics surges on Avlayah???s FDA approval, PRV sale and pipeline progress, but partnership changes and trial setbacks remain in focus.
- Zacks · Jun 23, 10:46 AM EDTRegenxbio Shares Rise on Plans to Resubmit Navsunli BLA for MPS IIRGNX shares jump after FDA alignment on next steps for Navsunli, paving the way for a planned MPS II BLA resubmission in Q3 2026.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Denali Therapeutics Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.